What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Cell Signalling: Principles, Pathways, and Mechanisms

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Cell Signalling

What is Cell Signalling?

Cell signalling is the process by which cells detect and respond to extracellular information, coordinating their behaviour with the demands of the organism. A signalling event begins when a signalling molecule—the ligand—binds to a specific receptor protein, either on the cell surface or inside the cell. This binding event triggers a cascade of intracellular molecular changes that ultimately alter the cell's behaviour, whether that means changing gene expression, modifying metabolism, altering cell shape, or initiating division or death.

The fundamental logic of cell signalling is information transfer: an extracellular stimulus is converted into an intracellular response. This conversion requires three core components: a signal (the ligand), a receiver (the receptor), and an effector (the downstream machinery that executes the response). Between receptor activation and effector function lies the process of signal transduction—a series of biochemical reactions that amplify, distribute, and integrate the incoming information.

Why Cells Communicate

Cells communicate for several essential reasons. In multicellular organisms, signalling coordinates development, maintains tissue homeostasis, and enables rapid responses to environmental changes. Without signalling, a multicellular organism would be a disorganised mass of cells rather than a functional entity. Signalling controls:

Cell division and differentiation — determining when cells proliferate and what specialised functions they adopt
Metabolic regulation — matching nutrient uptake and energy production to physiological demand
Immune responses — enabling immune cells to detect pathogens and coordinate attacks
Apoptosis — programmed cell death that removes damaged or superfluous cells
Tissue repair — coordinating proliferation and migration of cells after injury

Even unicellular organisms use signalling. Yeast cells communicate via mating pheromones, and bacteria use quorum sensing to coordinate population-level behaviours like biofilm formation. The molecular machinery of signalling is ancient and highly conserved across eukaryotes, which is why studying model organisms such as yeast, worms, and flies reveals principles that apply directly to human biology.

Types of Cell Signalling

Signalling can be classified by the distance over which the signal travels and the route by which it reaches its target cell.

Autocrine Signalling

In autocrine signalling, a cell releases a ligand that binds to receptors on its own surface. This creates a self-stimulatory loop. Autocrine signalling is common in the immune system, where activated T cells secrete interleukin-2 (IL-2) and simultaneously express the IL-2 receptor, driving their own clonal expansion. Autocrine loops are also a hallmark of cancer: tumour cells frequently secrete growth factors that stimulate their own proliferation, reducing their dependence on external growth signals.

Paracrine Signalling

Paracrine signalling involves the release of ligands that diffuse through the extracellular space to act on nearby cells. The signal acts over short distances—typically micrometres to a few millimetres—and is rapidly diluted or degraded. Neurotransmitters are classic paracrine signals: acetylcholine released at a neuromuscular junction diffuses across the synaptic cleft (about 20–50 nm) to activate receptors on the muscle fibre. Growth factors such as fibroblast growth factor (FGF) and transforming growth factor-β (TGF-β) also act in a paracrine manner during development and wound healing.

Endocrine Signalling

Endocrine signalling uses the circulatory system to deliver hormones over long distances. Endocrine glands—such as the pancreas, thyroid, and adrenal glands—secrete hormones into the blood, where they travel to target cells throughout the body. Insulin, for example, is secreted by pancreatic β-cells and acts on liver, muscle, and adipose tissue to promote glucose uptake. Endocrine signals can persist in the circulation for minutes to hours, enabling sustained physiological responses such as growth, metabolism, and reproduction.

Juxtacrine Signalling

Juxtacrine signalling (also called contact-dependent signalling) requires direct physical contact between the signalling cell and the target cell. The ligand remains anchored to the plasma membrane of the signalling cell and binds to a receptor on the adjacent cell. The Notch pathway is the archetypal juxtacrine system: the Notch receptor on one cell binds the Delta-like or Jagged ligand on a neighbouring cell, triggering proteolytic cleavage of the Notch intracellular domain, which then translocates to the nucleus to regulate gene expression. Juxtacrine signalling is critical during development, where it establishes boundaries between cell populations and controls cell fate decisions.

Signalling Type	Distance	Route	Example	Speed
Autocrine	Self	Extracellular fluid	IL-2 in T cells	Minutes
Paracrine	Short (µm–mm)	Diffusion	Neurotransmitters, FGF	Milliseconds to minutes
Endocrine	Long (cm–m)	Bloodstream	Insulin, cortisol	Seconds to hours
Juxtacrine	Direct contact	Membrane-bound ligand	Notch-Delta	Minutes to hours

Signalling Molecules and Receptors

Ligand Types

Ligands are chemically diverse and can be classified into several categories:

Hormones — endocrine signals such as insulin (peptide), cortisol (steroid), and thyroxine (amino acid derivative). Peptide hormones are hydrophilic and cannot cross the plasma membrane; steroid hormones are lipophilic and diffuse freely through membranes.
Growth factors — polypeptides that stimulate cell proliferation and differentiation, including epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and nerve growth factor (NGF).
Neurotransmitters — small molecules such as acetylcholine, dopamine, and glutamate that mediate rapid synaptic transmission.
Cytokines — signalling proteins of the immune system, including interleukins, interferons, and tumour necrosis factor (TNF).
Gasotransmitters — small gaseous molecules including nitric oxide (NO) and carbon monoxide (CO) that diffuse across membranes and activate intracellular enzymes.

The chemical nature of a ligand determines where its receptor is located. Hydrophilic ligands (peptides, neurotransmitters, growth factors) cannot cross the lipid bilayer and must bind cell-surface receptors. Hydrophobic ligands (steroids, thyroid hormone, retinoic acid) can diffuse into the cell and bind intracellular receptors.

Cell Surface Receptors

Cell-surface receptors fall into four major classes:

1. Ion channel-coupled receptors (ionotropic receptors). These are ligand-gated ion channels. Binding of the neurotransmitter causes a conformational change that opens the channel pore, allowing specific ions to flow down their electrochemical gradient. The nicotinic acetylcholine receptor at the neuromuscular junction is a pentameric channel that opens to admit Na⁺ and K⁺, depolarising the muscle membrane within milliseconds.

2. G protein-coupled receptors (GPCRs). GPCRs are seven-transmembrane-domain proteins that activate heterotrimeric G proteins upon ligand binding. This is the largest receptor family, with over 800 members in humans, and it mediates responses to hormones, neurotransmitters, odours, and light. GPCR signalling is discussed in detail in the signal transduction section.

3. Enzyme-linked receptors. These receptors have intrinsic enzymatic activity or associate directly with enzymes. The largest class is the receptor tyrosine kinases (RTKs), which phosphorylate tyrosine residues on themselves and downstream substrates. The EGF receptor (EGFR) and insulin receptor are RTKs. Their function is covered in detail in Tyrosine Kinase Function in Cell Signaling. Other enzyme-linked receptors include serine/threonine kinase receptors (for TGF-β) and guanylyl cyclase receptors (for atrial natriuretic peptide).

4. Cytokine receptors. These receptors lack intrinsic kinase activity but associate with cytoplasmic tyrosine kinases of the Janus kinase (JAK) family. They mediate responses to interleukins and interferons via the JAK-STAT pathway.

Intracellular Receptors

Intracellular receptors are typically ligand-activated transcription factors. The glucocorticoid receptor, for example, resides in the cytoplasm bound to heat shock proteins (Hsp90). Upon cortisol binding, the receptor dissociates from Hsp90, dimerises, and translocates to the nucleus, where it binds glucocorticoid response elements (GREs) in DNA to regulate transcription. Nuclear receptors share a conserved domain structure: an N-terminal activation domain, a DNA-binding domain with zinc fingers, and a C-terminal ligand-binding domain. Retinoic acid, vitamin D, and thyroid hormone all act through this mechanism.

Signal Transduction Mechanisms

Signal transduction converts receptor activation into a cellular response. This process typically involves second messengers—small intracellular signalling molecules—and phosphorylation cascades—sequential activation of protein kinases.

Second Messengers

Second messengers are small molecules that are generated or released in response to receptor activation and propagate the signal intracellularly. The major second messengers are:

Cyclic AMP (cAMP). Synthesised from ATP by adenylyl cyclase and degraded by phosphodiesterases. cAMP activates protein kinase A (PKA), which phosphorylates serine/threonine residues on target proteins. Typical intracellular cAMP concentrations rise from ~1 µM to ~10 µM upon maximal stimulation.
Calcium ions (Ca²⁺). The cytosolic Ca²⁺ concentration is normally ~100 nM, but can rise to ~1 µM upon signalling. Ca²⁺ enters the cytosol from the extracellular space through plasma membrane channels or from the endoplasmic reticulum (ER) through inositol 1,4,5-trisphosphate (IP₃) receptors and ryanodine receptors. Ca²⁺ binds calmodulin, which then activates Ca²⁺/calmodulin-dependent kinases (CaMKs).
Diacylglycerol (DAG) and IP₃. Produced by phospholipase C (PLC) cleavage of phosphatidylinositol 4,5-bisphosphate (PIP₂). DAG remains membrane-bound and activates protein kinase C (PKC); IP₃ diffuses to the ER and triggers Ca²⁺ release.
Phosphatidylinositol 3,4,5-trisphosphate (PIP₃). Produced by phosphoinositide 3-kinase (PI3K) phosphorylation of PIP₂. PIP₃ recruits proteins containing pleckstrin homology (PH) domains, such as AKT, to the plasma membrane.

Kinase Cascades

Protein phosphorylation is the most widespread post-translational modification in signalling. Kinases transfer the γ-phosphate of ATP to hydroxyl groups on serine, threonine, or tyrosine residues. Phosphatases reverse this reaction. A kinase cascade is a sequence in which one kinase phosphorylates and activates the next, amplifying the signal at each step.

The mitogen-activated protein kinase (MAPK) cascade is the canonical example. It consists of three tiers: a MAP kinase kinase kinase (MAPKKK) phosphorylates and activates a MAP kinase kinase (MAPKK), which phosphorylates and activates a MAP kinase (MAPK). Each kinase can phosphorylate multiple substrate molecules, so a single activated receptor can generate thousands of phosphorylated MAPK molecules within minutes. This amplification allows a weak extracellular signal to produce a robust cellular response.

G-Protein Coupled Receptor Pathways

GPCR signalling proceeds through a conserved sequence of events:

Ligand binding induces a conformational change in the GPCR, enabling it to act as a guanine nucleotide exchange factor (GEF) for the associated heterotrimeric G protein.
G protein activation. The G protein consists of Gα, Gβ, and Gγ subunits. In the resting state, Gα binds GDP. Upon receptor activation, GDP is exchanged for GTP, and the Gα subunit dissociates from Gβγ. Both Gα-GTP and free Gβγ can signal to downstream effectors.
Effector activation. Gαs stimulates adenylyl cyclase, increasing cAMP. Gαi inhibits adenylyl cyclase. Gαq activates phospholipase C-β, generating DAG and IP₃. Gβγ subunits can activate ion channels (e.g., G protein-coupled inwardly rectifying K⁺ channels, GIRKs) and PI3K.
Signal termination. The intrinsic GTPase activity of Gα hydrolyses GTP to GDP, allowing Gα to reassociate with Gβγ and return to the inactive state. This hydrolysis is accelerated by regulators of G protein signalling (RGS proteins), which can shorten the duration of G protein activation from seconds to milliseconds.

Major Signalling Pathways

MAPK/ERK Pathway

The MAPK/ERK pathway transmits proliferative and differentiation signals from RTKs to the nucleus. The pathway is activated when a growth factor such as EGF binds its receptor:

Receptor activation. EGF binding induces EGFR dimerisation and autophosphorylation of tyrosine residues in the receptor's cytoplasmic tail.
Adapter recruitment. The adapter protein Grb2 binds to a specific phosphotyrosine on the receptor via its SH2 domain. Grb2 then recruits the GEF SOS (Son of Sevenless) to the membrane.
Ras activation. SOS promotes GDP-GTP exchange on the small GTPase Ras. Ras-GTP is the active form.
Kinase cascade. Ras-GTP recruits and activates the MAPKKK Raf. Raf phosphorylates and activates MEK (MAPKK), which phosphorylates and activates ERK (MAPK).
Nuclear response. Activated ERK translocates to the nucleus and phosphorylates transcription factors such as Elk-1, driving expression of genes including c-Fos and c-Myc that promote cell cycle progression.

The pathway is tightly regulated. The protein phosphatase PP2A and the MAPK phosphatase MKP-1 dephosphorylate ERK, terminating the signal. Mutations that constitutively activate Ras (found in ~30% of human cancers) or Raf (e.g., the V600E mutation in melanoma) drive uncontrolled proliferation.

PI3K/AKT Pathway

The PI3K/AKT pathway promotes cell survival, growth, and metabolism. It is activated by RTKs, cytokine receptors, and GPCRs:

PI3K activation. PI3K is recruited to the plasma membrane, where it phosphorylates PIP₂ to generate PIP₃.
AKT recruitment. AKT binds PIP₃ via its PH domain and is recruited to the membrane, where it is phosphorylated at Thr308 by PDK1 and at Ser473 by mTORC2.
AKT substrates. Active AKT phosphorylates numerous targets: it inactivates the pro-apoptotic protein BAD, inhibits the transcription factor FOXO (promoting survival), activates mTORC1 (promoting protein synthesis), and promotes glucose uptake by stimulating GLUT4 translocation.

The pathway is antagonised by the tumour suppressor PTEN, a lipid phosphatase that dephosphorylates PIP₃ back to PIP₂. Loss of PTEN function—common in glioblastoma, prostate, and breast cancer—results in constitutive AKT activation.

JAK-STAT Pathway

The JAK-STAT pathway mediates signalling by cytokines and interferons. It is notable for its simplicity: the pathway does not use second messengers, and the transcription factors are activated directly by phosphorylation.

Cytokine binding. A cytokine such as interferon-γ binds its receptor, bringing two receptor subunits together.
JAK activation. Receptor-associated JAK kinases (JAK1, JAK2, JAK3, or TYK2) phosphorylate each other and then phosphorylate tyrosine residues on the receptor cytoplasmic tails.
STAT recruitment and activation. STAT (Signal Transducer and Activator of Transcription) proteins bind to the phosphotyrosines via their SH2 domains. JAKs then phosphorylate the STATs on a conserved tyrosine residue.
Dimerisation and nuclear translocation. Phosphorylated STATs dissociate from the receptor, dimerise via reciprocal SH2-phosphotyrosine interactions, and translocate to the nucleus to regulate gene transcription.

Different cytokine receptors activate different STAT family members. Interferon-γ activates STAT1, which drives expression of antiviral and pro-inflammatory genes. Interleukin-6 activates STAT3, which promotes cell survival and proliferation. The pathway is terminated by suppressors of cytokine signalling (SOCS) proteins, which are induced by STAT activity and inhibit JAKs—a classic negative feedback loop.

Wnt Pathway

The Wnt pathway controls cell fate during development and stem cell maintenance. The canonical (β-catenin-dependent) pathway operates as follows:

Resting state. In the absence of Wnt ligand, cytoplasmic β-catenin is constitutively phosphorylated by a destruction complex containing glycogen synthase kinase 3β (GSK3β), casein kinase 1α (CK1α), and the scaffold proteins Axin and APC. Phosphorylated β-catenin is ubiquitinated by β-TrCP and degraded by the proteasome.
Wnt binding. Wnt ligands bind to Frizzled receptors and the co-receptor LRP5/6. This recruits the protein Dishevelled (Dvl) and causes phosphorylation of LRP6.
Destruction complex inhibition. The destruction complex is inactivated, allowing β-catenin to accumulate in the cytoplasm.
Nuclear translocation. β-catenin enters the nucleus, where it displaces co-repressors from TCF/LEF transcription factors and recruits co-activators such as CBP/p300, driving expression of Wnt target genes including c-Myc and cyclin D1.

Aberrant Wnt signalling is a major driver of colorectal cancer. Approximately 80% of colorectal cancers carry mutations in APC, preventing β-catenin degradation and causing constitutive pathway activation. This topic is explored further in Wnt Signalling Pathway in Cancer.

Methods to Study Cell Signalling

Biochemical Assays

Western blotting is the workhorse of signalling research. Cells are lysed in a buffer containing protease and phosphatase inhibitors (typically 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, plus inhibitors), and proteins are separated by SDS-PAGE. After transfer to a membrane, the blot is probed with antibodies specific for phosphorylated forms of signalling proteins. For example, anti-phospho-ERK antibodies detect ERK activation, while anti-total-ERK antibodies confirm equal loading. This approach reveals both the timing and magnitude of pathway activation.

Kinase activity assays measure the enzymatic activity of a kinase directly. A purified kinase is incubated with a peptide substrate and [γ-³²P]ATP, and the incorporation of radioactive phosphate into the substrate is quantified. Alternatively, luminescent or fluorescent assays (e.g., ADP-Glo) measure ATP consumption.

Immunoprecipitation is used to study protein-protein interactions. An antibody against a protein of interest is used to pull that protein—along with its binding partners—out of a cell lysate. Subsequent Western blotting for candidate interactors reveals whether the interaction occurs under specific signalling conditions.

Microscopy and FRET

Immunofluorescence localises signalling proteins within cells. Cells are fixed, permeabilised, and stained with fluorescent antibodies. This reveals, for example, whether a transcription factor such as NF-κB has translocated from the cytoplasm to the nucleus upon stimulation. For live-cell imaging, proteins can be fused to fluorescent tags such as GFP.

Förster resonance energy transfer (FRET) reports real-time protein interactions and conformational changes. FRET occurs when two fluorophores are within 10 nm of each other and the emission spectrum of the donor overlaps the excitation spectrum of the acceptor. By fusing a protein of interest to a FRET donor-acceptor pair (e.g., CFP and YFP), researchers can detect conformational changes or binding events as changes in the FRET signal. FRET-based biosensors exist for cAMP, Ca²⁺, and kinase activity.

Genetic Approaches

CRISPR-Cas9 gene editing allows researchers to knock out or modify signalling genes. A guide RNA directs the Cas9 nuclease to a specific genomic locus, creating a double-strand break that is repaired by non-homologous end joining, typically producing a frameshift mutation. Knockout cell lines reveal the requirement of a particular gene for a signalling response.

CRISPR screens scale this approach to the entire genome. A pooled library of guide RNAs targeting all ~20,000 human genes is introduced into cells, and the cells are subjected to a selective pressure (e.g., a drug that inhibits a signalling pathway). Guide RNAs that are depleted or enriched in surviving cells identify genes that modulate the response. This approach has identified resistance mechanisms to targeted cancer therapies.

Reporter assays measure pathway activity through transcriptional output. A reporter construct contains a promoter with the relevant response elements driving expression of luciferase or GFP. For example, a NF-κB reporter contains multiple κB sites upstream of luciferase; the amount of luminescence reflects NF-κB transcriptional activity. These assays are widely used in drug screening.

Regulation and Termination of Signalling

Signalling must be terminated to prevent uncontrolled responses. Multiple mechanisms operate at different levels of the pathway.

Receptor Desensitization

Receptor desensitization reduces the responsiveness of a receptor upon repeated or prolonged stimulation. For GPCRs, the process involves:

Phosphorylation. G protein-coupled receptor kinases (GRKs) phosphorylate the activated receptor on its cytoplasmic tail.
Arrestin binding. β-arrestin binds the phosphorylated receptor, physically blocking G protein coupling and thereby terminating G protein signalling.
Internalisation. β-arrestin also links the receptor to clathrin-coated pits, promoting endocytosis. Internalised receptors are either recycled to the plasma membrane (resensitisation) or targeted to lysosomes for degradation (downregulation).

RTKs are similarly downregulated. Ligand binding triggers receptor ubiquitination by the E3 ligase Cbl, which marks the receptor for endocytosis and lysosomal degradation.

Phosphatases

Protein phosphatases reverse kinase-mediated phosphorylation. The major classes are:

Serine/threonine phosphatases — PP1, PP2A, and PP2B (calcineurin). PP2A dephosphorylates ERK, AKT, and many other kinases, acting as a global brake on signalling.
Tyrosine phosphatases — including PTP1B and SHP2. PTP1B dephosphorylates the insulin receptor, and its inhibition enhances insulin sensitivity.
Dual-specificity phosphatases (DUSPs) — dephosphorylate both tyrosine and serine/threonine residues. MKP-1 (DUSP1) dephosphorylates ERK in the nucleus, terminating MAPK signalling.

The balance between kinase and phosphatase activity determines the steady-state phosphorylation level of any signalling protein.

Negative Feedback

Negative feedback loops limit the amplitude and duration of signalling. These loops can operate at multiple levels:

Transcriptional feedback. Many signalling pathways induce expression of their own inhibitors. The MAPK pathway induces MKP-1; the JAK-STAT pathway induces SOCS proteins; the NF-κB pathway induces IκBα, which sequesters NF-κB in the cytoplasm.
Post-translational feedback. Active kinases can phosphorylate upstream components to inhibit them. For example, ERK phosphorylates SOS, reducing its GEF activity and dampening Ras activation.
Ligand-induced feedback. Signalling can induce expression of secreted antagonists. The Wnt pathway induces expression of the secreted Frizzled-related protein sFRP, which sequesters Wnt ligands.

Feedback loops can also be positive, generating switch-like responses or oscillations. The p53-Mdm2 loop, in which p53 induces Mdm2 (which degrades p53), produces oscillations in p53 levels after DNA damage.

Cell Signalling in Disease and Therapy

Oncogenic Signalling

Cancer is fundamentally a disease of aberrant signalling. The hallmarks of cancer—sustained proliferation, evasion of apoptosis, and metastasis—all arise from signalling dysregulation. Key mechanisms include:

Constitutive receptor activation. Mutations that cause RTKs to dimerise and signal without ligand. The EGFRvIII mutation in glioblastoma lacks the extracellular domain and signals constitutively. HER2 amplification in breast cancer produces excess receptor that dimerises spontaneously.
Activating mutations in downstream kinases. The BRAF V600E mutation, found in ~50% of melanomas, renders Raf constitutively active, driving ERK signalling independent of Ras. Mutations in PI3K (PIK3CA) are found in many solid tumours.
Loss of negative regulators. PTEN loss activates the PI3K/AKT pathway. NF1, a negative regulator of Ras, is mutated in neurofibromatosis and some gliomas.
Dysregulated transcription factors. MYC is amplified in many cancers, and β-catenin accumulates in colorectal cancers with APC mutations.

Targeted Therapies

The detailed understanding of signalling pathways has enabled the development of targeted therapies that inhibit specific signalling components:

Kinase inhibitors. Imatinib (Gleevec) inhibits the BCR-ABL fusion kinase in chronic myeloid leukaemia. Gefitinib and erlotinib inhibit EGFR in non-small cell lung cancer. Vemurafenib inhibits BRAF V600E in melanoma. These drugs are typically small molecules that compete with ATP for binding to the kinase active site.
Monoclonal antibodies. Trastuzumab (Herceptin) binds HER2 and blocks its signalling in HER2-positive breast cancer. Cetuximab binds EGFR and prevents ligand-induced activation.
Proteasome inhibitors. Bortezomib inhibits the proteasome, preventing degradation of IκB and thereby blocking NF-κB signalling in multiple myeloma.

Resistance to targeted therapies is a major clinical challenge. Tumours frequently acquire secondary mutations in the drug target or activate bypass signalling pathways. Combination therapies that target multiple nodes in a pathway are increasingly used to delay resistance.

Common Pitfalls and Study Tips

Misconceptions

Students commonly misunderstand several aspects of cell signalling:

"One ligand, one pathway, one response." In reality, signalling pathways are highly interconnected. A single ligand can activate multiple pathways (EGF activates both MAPK and PI3K), and different cell types respond differently to the same ligand depending on which receptors and downstream components they express.

"Phosphorylation always activates." Phosphorylation can either activate or inhibit a protein, depending on which residue is modified. For example, phosphorylation of AKT at Thr308 and Ser473 activates it, but phosphorylation of GSK3β at Ser9 inhibits it.

"Second messengers are always small molecules." While cAMP and Ca²⁺ are small molecules, some signals are transmitted by protein-protein interactions alone. The JAK-STAT pathway uses no second messengers whatsoever.

"Receptors are always on the cell surface." Steroid hormone receptors are intracellular, and some receptors (such as the aryl hydrocarbon receptor) are nuclear.

"Signalling is linear." Pathways contain extensive crosstalk, feedback, and feed-forward loops. The MAPK and PI3K pathways inhibit each other at multiple points, and the output of a pathway depends on the cellular context.

Exam Preparation Tips

Learn the canonical pathways in order. For each major pathway (MAPK, PI3K/AKT, JAK-STAT, Wnt), memorise the sequence: ligand → receptor → adapter → kinase → transcription factor → target gene. Draw the pathway from memory repeatedly.
Understand the logic, not just the names. Ask yourself: what is the signal? What is the receptor? What is the second messenger? What is the effector? What turns the signal off?
Compare and contrast. Make tables comparing GPCR and RTK signalling, or comparing the four types of cell signalling. Examiners frequently ask for comparisons.
Know the experimental evidence. Be able to explain how Western blotting with phospho-specific antibodies demonstrates pathway activation, and how CRISPR knockout reveals gene function.
Connect signalling to disease. For each pathway, know one example of a disease caused by its dysregulation and one drug that targets it.
Practice with diagrams. Signalling is inherently visual. Redraw each pathway from memory until you can do it without referring to notes.

Frequently Asked Questions

What is cell signalling?

Cell signalling is the process by which cells detect and respond to extracellular stimuli. It involves the binding of a signalling molecule (ligand) to a receptor, followed by a cascade of intracellular events that produce a specific cellular response. This process underlies all coordinated behaviour in multicellular organisms, including development, immunity, metabolism, and tissue repair.

What are the types of cell signalling?

The four main types are autocrine (a cell signals to itself), paracrine (signalling to nearby cells via diffusion), endocrine (signalling through the bloodstream over long distances), and juxtacrine (signalling through direct cell-cell contact). These types differ in the distance the signal travels and the route it takes.

How does cell signalling occur?

Cell signalling occurs through a sequence of events: ligand synthesis and release, ligand transport to the target cell, ligand binding to a specific receptor, receptor activation, signal transduction through intracellular cascades, and finally a cellular response such as changes in gene expression, metabolism, or cell shape. The signal is then terminated by mechanisms such as receptor desensitisation and phosphatase activity.

What is a ligand in cell signalling?

A ligand is any molecule that binds specifically to a receptor protein. Ligands include hormones, growth factors, neurotransmitters, cytokines, and even physical stimuli such as light (which binds the GPCR rhodopsin). The binding of a ligand to its receptor is highly specific, like a key fitting a lock, and typically occurs with dissociation constants (Kd) in the nanomolar to micromolar range.

What are second messengers?

Second messengers are small intracellular molecules that are generated or released in response to receptor activation and propagate the signal within the cell. The major second messengers are cyclic AMP (cAMP), calcium ions (Ca²⁺), diacylglycerol (DAG), inositol trisphosphate (IP₃), and phosphatidylinositol trisphosphate (PIP₃). They amplify the signal and activate downstream effectors such as protein kinases.

What is the difference between a receptor and an effector?

A receptor is the protein that binds the ligand and initiates the signalling response. An effector is the downstream protein that executes the cellular response. For example, in the β-adrenergic receptor pathway, the receptor is the β-adrenergic GPCR, and the effector is adenylyl cyclase, which produces cAMP. In many pathways, the receptor activates an intermediate protein (such as a G protein) that then activates the effector.

Why is cell signalling important?

Cell signalling is essential for life. It coordinates development, maintains tissue homeostasis, enables immune responses, regulates metabolism, and controls cell division and death. Defects in cell signalling underlie numerous diseases, including cancer, diabetes, autoimmune disorders, and neurological conditions. Understanding cell signalling is therefore fundamental to both basic biology and clinical medicine.

Key Takeaways

Cell signalling involves three core components: a ligand, a receptor, and an effector, connected by signal transduction cascades.
Signalling is classified by distance: autocrine (self), paracrine (neighbouring cells), endocrine (blood-borne), and juxtacrine (contact-dependent).
Receptors fall into four classes: ion channels, GPCRs, enzyme-linked receptors, and intracellular/nuclear receptors.
Signal transduction relies on second messengers (cAMP, Ca²⁺, DAG, IP₃, PIP₃) and phosphorylation cascades that amplify the signal.
Major pathways—MAPK/ERK, PI3K/AKT, JAK-STAT, and Wnt—share common logic but use distinct molecular components and regulate different cellular outcomes.
Signalling is terminated by receptor desensitisation, phosphatases, and negative feedback loops; dysregulation of these mechanisms drives disease.
Experimental methods including Western blotting, FRET, and CRISPR screens are essential tools for dissecting signalling mechanisms.